Editor's note: On Jan. 19, 2012, the pharmaceutical companies AstraZeneca and Bristol-Myers Squibb announced that the FDA rejected their approval request for dapagliflozin, calling for more research data on the drug’s benefits and risks. Both companies say they remain committed to developing the drug and will work with the FDA to determine the next steps.
July 19, 2011 -- In a 9-6 vote, an advisory panel said the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight.
The split vote, as well as panelist comments, makes it uncertain whether the FDA will approve the drug, jointly made by Bristol-Myers Squibb and AstraZeneca. The FDA will certainly ask the companies to gather more data on side effects; the key question is whether the agency will ask for this data before or after approval.
Dapagliflozin is the first in a new class of diabetes drugs. Normally, the kidney recycles sugar back into the body. But dapagliflozin inhibits a transporter molecule called SGLT-2. The result: Sugar passes out of the body in the urine, lowering blood sugar without affecting insulin levels.
A downside to the drug is that diabetes often damages the kidneys. Even moderate loss of kidney function makes dapagliflozin much less effective. The drug would be given only to patients with sufficient kidney function, but some panelists questioned the value of a proposed test to determine which patients could take dapagliflozin.
And the drug has side effects. All that sugar in the urine increases patients' risk of urinary tract and genital infections. There are other worries, too -- including dehydration and heat intolerance -- but members of the advisory committee were far less worried about these side effects than about the possible risk of cancer and liver toxicity.